Immunotherapy, Bringing It All Together: The Next Generation of Approaches & Combinations Moderator: Axel Hoos, MD, Vice President, Oncology Research and Development, GlaxoSmithKline Panelists: • Neil Berinstein, MD, Affiliate Scientist, Sunnybrook Research Institute • Paul Higham, Chief Executive Officer, Immatics • Sara Zaknoen, MD, CMO, Polynoma, LLC • Dennis L. Panicali, Ph.D, Vice President, Technical Operations Bavarian __Nordic ImmunoTherapeutics • Charles J. Link, Jr. MD, Chairman, Chief Executive & Scientific Officer at __NewLink Genetics Corp
12
Embed
Immunotherapy, Bringing It All Together: The Next Generation of … · 2019. 10. 30. · Immunotherapy, Bringing It All Together: The Next Generation of Approaches & Combinations
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Immunotherapy, Bringing It All Together: The Next Generation of Approaches & Combinations Moderator: Axel Hoos, MD, Vice President, Oncology Research and Development, GlaxoSmithKline Panelists: • Neil Berinstein, MD, Affiliate Scientist, Sunnybrook Research Institute • Paul Higham, Chief Executive Officer, Immatics • Sara Zaknoen, MD, CMO, Polynoma, LLC • Dennis L. Panicali, Ph.D, Vice President, Technical Operations Bavarian __Nordic ImmunoTherapeutics • Charles J. Link, Jr. MD, Chairman, Chief Executive & Scientific Officer at __NewLink Genetics Corp
Paul G Higham March 2013 / New York
immatics – at a glance
Multi-peptide cancer vaccines developed from the X-President identification and validation platform
Since 2004 immatics has:
• Established and continuously evolved its proprietary technology platform XPRESIDENTTM
• Built a robust pipeline with three high potential vaccines in clinical development:
Decrease of myeloid suppressor cells in sunitinib-treated patients
Inhibition of Tregs in IMA901 phase 2 study by sunitinib pre-treatment
IMA901 phase II data
p = 0.012
6
IMA901 Phase 2 Biomarker programm >400 biomarkers analysed pre-treatment
147 Cytokines / Chemokines e.g. TNF-R1,
TGF-beta, IL-10
16 Biogenic Amines
e.g. kynurenine, serotonin
21 Amino Acids e.g. Trp
41 Carnitines
e.g. C16 (hexadecanoyl
carnitine)
106 Lipids
(lyso-)phosphatidyl cholines,
sphingomyelins
36 Cellular Analyses
•CD3 zeta nitrotyrosin (6) •Treg: Flow, PCR (15)
•MDSCs (12) •TH17 (3)
21 Clinical
Parameters e.g. Pre-treatment,
Metastases, Staging
15 Clinical
Chemistry e.g. electrolytes, serum proteins,
glucose
17 Classical Hematology/
Coagulation e.g. lymphocytes, neutrophils,
hemoglobin
6 Patient
Parameters e.g. gender, age,
CMV
12 Urine Analyses
e.g. protein, glucose
7
IMA901 Phase 2 Study ApoA1/CCL17 biomarker signature
Logrank p-values, FU5
HR = 0.17 p=0.000077
BM pos (75%)
BM neg (25%)
(TARC+ or ApoA1+, 50% of patients)
(TARC+ & ApoA1+, 25% of patients)
(TARC- & ApoA1-, 25% of patients)
biomarker score of 1 or 2 vs. score of 0 biomarker score of 2 vs. score of 1 vs. score of 0
8
9 Predicting Response – in vitro to in vivo immune response validation platform
• Principle: Priming of naïve precursor T cells specific for TUMAPs • Use of artificial antigen presenting cells allows high degree of standardization • The platform indicates whether circulating specific precursor T cells exist
10 In vitro veritas!
R and p values from spearman correlation Linear regression with 90% confidence intervals
In vitro immunogenicity from healthy donors was associated with in vivo immune responses in patients in 4 independent clinical studies
Collaborating and Partnering with Large Pharma/Biotech
• Attitudes are changing towards cancer immunotherapy • Further positive data needed to continue to drive this change
• Understanding?
• Where/how could we best work together?
11
Immunotherapy, Bringing It All Together: The Next Generation of Approaches & Combinations Moderator: Axel Hoos, MD, Vice President, Oncology Research and Development, GlaxoSmithKline Panelists: • Neil Berinstein, MD, Affiliate Scientist, Sunnybrook Research Institute • Paul Higham, Chief Executive Officer, Immatics • Sara Zaknoen, MD, CMO, Polynoma, LLC • Dennis L. Panicali, Ph.D, Vice President, Technical Operations Bavarian __Nordic ImmunoTherapeutics • Charles J. Link, Jr. MD, Chairman, Chief Executive & Scientific Officer at __NewLink Genetics Corp